Grace Therapeutics, Inc GRCE

Healthcare

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc

Bullboard Posts

Comment by EternalPonzion Jan 14, 2020 9:46am

93 Views

Post# 30550418

RE:sorry - article may have been cut off - Not good for ACST

Yes read this too. Another negative sound bite article that does not elaborate on Acasti's results to give true and proper context. CaPre is based on 'krill' oil with very unique characteristics. To group this with other 'fish' oils is erroneous. Any opportunity to use the word 'failure' cannot be overlooked in articles written by those who are likely tied to Amarin in some way.

Bullboard Posts

Barrick Gold employees detained in Mali amid ongoing dispute